777 replies to this topic

[ImmInst]

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of ...
Benzinga - 4 hours ago

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test.

View the full article

[ImmInst]

BioTime Inc.: BioTime Subsidiary ES Cell International and GE Healthcare Cross ...
The Wall Street Transcript - 11 hours ago

15, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. ("ESI") and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI's stem cell patents and ESI ...

View the full article

[ImmInst]

Form 8-K BIOTIME INC For: Dec 12
StreetInsider.com (subscription) - 15 hours ago

Any statements that are not historical fact (including, but not limited to statements that contain words such as “may, “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking ...

View the full article

[ImmInst]

BioTime Inc.: BioTime Appoints Angus C. Russell to Board of Directors
The Wall Street Transcript - Dec 15, 2014

15, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to ...

View the full article

[ImmInst]

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of ...
Business Wire (press release) - Dec 15, 2014

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test.

View the full article

[ImmInst]

BioTime Appoints Adi Mohanty Chief Operating Officer
Business Wire (press release) - 1 hour ago

BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today announced the appointment of Adi Mohanty to the position of Chief ...

View the full article

[ImmInst]

BioTime Inc.: BioTime Subsidiary OncoCyte Corporation Appoints William Annett ...
The Wall Street Transcript - Jan 12, 2015

12, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that William Annett has been appointed to OncoCyte's Board of Directors.

View the full article

[ImmInst]

BioTime Inc.: BioTime Announces Issuance of 14 New Patents in the Fields of ...
The Wall Street Transcript - 1 hour ago

26, 2015-- BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell ...

View the full article

[ImmInst]

ESI BIO – A Division of BioTime Inc. Announces New UK Distribution Agreement ...
PharmiWeb.com (press release) - Jan 27, 2015

ESI BIO - A Division of BioTime Inc. markets and distributes stem cell related research products provided by BioTime and its subsidiary companies.

View the full article

[ImmInst]

BioTime Inc.: ESI BIO - A Division of BioTime, Inc. Announces New UK ...
The Wall Street Transcript - 2 hours ago

ALAMEDA, Calif., January 27, 2015 - ESI BIO, the stem cell products division of BioTime, Inc., announces that its cGMP and research grade stem cell lines, reagents and cell matrix products are now available in the UK and Ireland through 2BScientific Ltd.

View the full article

[ImmInst]

Form 8-K BIOTIME INC For: Feb 06
StreetInsider.com - Feb 6, 2015

(BUSINESS WIRE)--February 6, 2015--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of OncoCyte's PanC-Dx™ diagnostic products for bladder and breast cancer, ...

View the full article

[ImmInst]

ESI BIO – A Division of BioTime, Inc., Announces Alliance Agreement with ...
Business Wire (press release) - 2 hours ago

BUSINESS WIRE)--ESI BIO, the stem cell products division of BioTime, Inc., providing stem cells and stem cell research reagents world-wide, and Pivotal Scientific Ltd, a company specializing in developing the international growth of biotech enterprises ...

View the full article

[ImmInst]

BioTime Inc.: ESI BIO – A Division of BioTime, Inc., Announces Alliance ...
The Wall Street Transcript - 2 hours ago

ALAMEDA, Calif., February 23, 2015 - ESI BIO, the stem cell products division of BioTime, Inc., providing stem cells and stem cell research reagents world-wide, and Pivotal Scientific Ltd, a company specializing in developing the international growth ...

View the full article

[ImmInst]

BioTime Inc.: Asterias Biotherapeutics to Report Fourth Quarter and Full Year ...
The Wall Street Transcript - 3 hours ago

MENLO PARK, Calif., March 2, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release fourth quarter and full year 2014 ...

View the full article

[ImmInst]

Form 8-K BIOTIME INC For: Apr 20
StreetInsider.com - 20 hours ago

(BUSINESS WIRE)--April 20, 2015--BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced positive clinical results of PanC-Dx™, OncoCyte's class of proprietary, non-invasive cancer diagnostic tests, in detecting the most ...

OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type ... - Business Wire (press release)
Cookies on Pharmiweb.Com - PharmiWeb.com (press release)

View the full article

[ImmInst]

BioTime Inc. (BTX) is Trading Higher on Unusual Volume for April 22
Equities.com - 8 hours ago

BioTime Inc. (BTX) experienced unusually high volume on Apr. 22, as the stock gained 3.85% to a closing price of $5.66. The stock saw 622,935 shares trade hands over the course of the day on 2,340 trades.

View the full article

[ImmInst]

BioTime Inc. (BTX) Hits New 52-week High During April 24 Session
Equities.com - 7 hours ago

BioTime Inc. (BTX) hit a new 52-week high yesterday, reaching a peak of $5.95 after opening at $5.95 and closing at $5.72 for a move of $-2.72%.

View the full article

[ImmInst]

BioTime Inc. (BTX) Hits New 52-week High During April 24 Session
Equities.com - 14 hours ago

BioTime Inc. is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make ...

View the full article

[ImmInst]

Today's Hot List: BioTime, Inc. (NYSEMKT:BTX), The Interpublic Group of ...
Stock Transcript - 2 hours ago

BioTime, Inc. (NYSEMKT:BTX) belongs to Healthcare sector. Its weekly performance is 9.58%. On last trading day company shares ended up $5.72.

View the full article

[ImmInst]

Form 8-K BIOTIME INC For: Apr 27
StreetInsider.com - 2 hours ago

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed.

View the full article

[ImmInst]

BioTime Inc. (BTX) is Trading Lower on Unusual Volume for April 27
Equities.com - Apr 27, 2015

BioTime Inc. (BTX) experienced unusually high volume on Apr. 27, as the stock lost 1.57% to a closing price of $5.63. The stock saw 787,798 shares trade hands over the course of the day on 3,146 trades.

View the full article

[ImmInst]

BioTime Inc.: Asterias Biotherapeutics to Report First Quarter Results on May ...
The Wall Street Transcript - 15 hours ago

MENLO PARK, Calif., April 30, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release first quarter financial and ...

View the full article

[ImmInst]

Stock Highlights: BioTime, Inc. (NYSEMKT:BTX), Concert Pharmaceuticals, Inc ...
Stock Transcript - 4 hours ago

BioTime, Inc. (NYSEMKT:BTX) belongs to Healthcare sector. Its weekly performance is -12.76%. On last trading day company shares ended up $5.13.

View the full article

[ImmInst]

Best Stocks: DURECT Corporation (NASDAQ:DRRX), BioLineRx, Ltd. (NASDAQ ...
Stock Transcript - 32 minutes ago

On 27 April, BioTime, Inc. (NYSEMKT:BTX) announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime's wholly-owned subsidiary ES Cell International Pte Ltd (ESI, Singapore) will be used by UC Irvine scientist Dr.

View the full article

[ImmInst]

Top Stories: BioTime, Inc. (NYSEMKT:BTX), Heat Biologics, Inc. (NASDAQ:HTBX ...
Stock Transcript - 1 hour ago

BioTime, Inc. (NYSEMKT:BTX) belongs to Healthcare sector. Its weekly performance is -9.58%. On last trading day company shares ended up $5.19.

View the full article

[ImmInst]

Stocks in Focus: Avon Products Inc. (NYSE:AVP), BioTime, Inc. (NYSEMKT:BTX ...
Stock Transcript - 2 hours ago

Avon Products Inc. (NYSE:AVP) belongs to Consumer Goods sector. Its net profit margin is -6.30% and weekly performance is -11.64%.

View the full article

[ImmInst]

Monday's Morning Outlook: American Water Works Company, Inc. (AWK ...
WallStreet Scope - 48 minutes ago

BioTime, Inc. (BTX) of the Biotechnology sector closed out the day Friday at $5.24, a gain of 0.38% with a return on investment of -129.30% trading at a volume of 167,103 shares.

View the full article

[ImmInst]

Stocks in Focus: Avon Products Inc. (NYSE:AVP), BioTime, Inc. (NYSEMKT:BTX ...
Stock Transcript - 20 hours ago

Avon Products Inc. (NYSE:AVP) belongs to Consumer Goods sector. Its net profit margin is -6.30% and weekly performance is -11.64%.

View the full article

[ImmInst]

BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate ...
Business Wire (press release) - 13 hours ago

BioTime, Inc., a pioneer in regenerative medicine, is a clinical-stage biotechnology company. BioTime and its subsidiaries are leveraging their industry-leading experience in pluripotent stem cell technology and a broad intellectual property portfolio ...

View the full article

[ImmInst]

Active Watch List: ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC ...
Stock Transcript - 1 hour ago

BioTime, Inc. (NYSEMKT:BTX) shares fell -1.15% in last trading session and ended the day at $5.18. BTX Gross Margin is 81.50% and its return on assets is -70.10%.

View the full article